Vertex Pharmaceuticals Incorpor

Disclaimer : Sections of this page are auto-generated by Artificial Intelligence and shall not be understood as Investment Advice
This page was updated : 2023-04-26 08:26:30 UTC

Vertex Pharmaceuticals has had a year of growth and has a promising portfolio. Bullish news may push the company's stock above its 52-week high.

Based on these articles
  1. Vertex to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference on June 13
  2. Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings
  3. Vertex Pharmaceuticals Rally Likely Not Over
  4. Vertex Pharmaceuticals Offers Value Despite Recent Gains
Business Overview

As an investment analyst, Vertex Pharmaceuticals Incorpor's business model can be described as a biotechnology company that focuses on discovering, developing, and commercializing innovative medicines for serious diseases. Vertex's primary focus is on developing therapies for cystic fibrosis (CF), a genetic disease that affects the lungs and digestive system. Vertex's business model is centered around its research and development (R&D) efforts, which are aimed at identifying and developing new drugs that can treat CF and other serious ...

Yahoo - Business Overview

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations. The ...

Risk Rating (Yahoo)


ESG Score (Yahoo)


Market Cap (USD)

83.78 B

AI Rank (finclout)


Flags & Key Risks
Negative Revenue Trend Insiders are selling Pre-market negative on higher volumes
  • Regulatory risk - Vertex Pharmaceuticals operates in a highly regulated industry, and any changes in regulations or failure to obtain necessary approvals could negatively impact the company's operations and financial performance.
  • Competition risk - The biotechnology industry is highly competitive, and Vertex Pharmaceuticals faces competition from established players as well as new entrants. This could impact the company's market share and profitability.
  • Clinical trial risk - Vertex Pharmaceuticals' success depends on the success of its clinical trials. Any setbacks or failures in these trials could negatively impact the company's financial performance.
  • Intellectual property risk - Vertex Pharmaceuticals relies heavily on its intellectual property, and any infringement or loss of patents could negatively impact the company's operations and financial performance.
  • Market risk - Vertex Pharmaceuticals' stock price is subject to market volatility and fluctuations, which could impact the value of an investor's investment.

SWOT Analysis









Thesis for Vertex Pharmaceuticals Incorpor


Vertex Pharmaceuticals has a strong pipeline of drugs in development, including potential treatments for cystic fibrosis and other genetic diseases. The company has a track record of successful drug approvals and a strong financial position, which bodes w ...


Vertex Pharmaceuticals operates in a highly competitive and regulated industry, which presents both opportunities and challenges. While the company has a strong pipeline and financial position, there are risks associated with drug development and ...


Vertex Pharmaceuticals faces significant competition in the pharmaceutical industry, and its success is highly dependent on the approval and commercial success of its drug pipeline. There are also regulatory and legal risks associated with drug ...

News Coverage

No filings found for
No lawsuits found for
Offcanvas top
Offcanvas left






Offcanvas bottom
Some text as placeholder. In real life you can have the elements you have chosen. Like, text, images, lists, etc.